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Introduction: The coagulation factor 13 has a fundamental role in homeostasis, protective 
effects on thrombosis, and some other associated diseases. Due to increasing the chronic 
coagulability of major thalassemic patients, this study was conducted with aim determining 
the prevalence of Val34LeuFXIII polymorphism in the thalassemic patients. 
Materials and methods: The present case-control study was conducted on 100 patients with 
major thalassemia with a gender ratio of 50 females and 50 males as case and 100 healthy 
persons as control with a gender combination of 50 males and 50 females that were selected 
with the referral order on the different days. DNA extraction and the polymerase chain 
reaction (PCR) were conducted. The genotypes of this polymorphism were identified by 
RFLP technique and Cfo1 restrictive enzyme. The analysis of data was conducted by SPSS 
11.5 software, chi-square, and logistic regression statistical tests. P<0.05 was considered as a 
significant level. 
Results: The prevalence of FXIIIVal34Leu polymorphism was achieved 18% that its 83% 
and 17% were related, respectively, to the heterozygote genotype (Val/Leu) and homozygote 
genotype (Leu/Leu). 82% of these patients also had the genotype of wild type (Val/Val) 
among which 66.7% and 33.3 % of mutants were, male and female. 26% of them had 
Val34Leu polymorphism in the control group that 73% and 27% of them were, respectively, 
heterozygotic and homozygotic. 
Conclusion: So far, the prevalence of FXIIIA Val34Leu polymorphism has not been reported 
in patients with Major thalassemia. A significant relationship wasn’t seen in this study 
between the prevalence of FXIIIVal34Leu polymorphism in the thalassemic patients 
compared with the control group. 
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Introduction 
The coagulation XIII factor of blood is an 
inactive enzyme with 731 amino acids that 
is converted into an active 
transglutaminase by thrombin and calcium 
ion. Its duty is binding to the end of alpha 
and gamma amino group of fibrin chains. 
This binding causes to increase the 
strength of fibrin network. Its plasmatic 
and intracellular structures are, 
respectively, tetrameric and dimer. Its 
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form of the plasma has been formed from 
two similar pre-enzymatic subunits 
(FXIIIA) and two carrier / transporter 
protein subunits (FXIIIB). 
The gene of FXIIIA subunit has had 200 
kb of length, is located in the area of P24-
256 bands (1). The active XIII factor is 
essential for maintaining homeostasis (2), 
as well as has a role in the vaginal 
delivery, wound healing, cellular 
migration and clot resilience (clot 
retraction) and its defects is associated 
with the wound non-healing, risk of 
miscarriage and haemorrhagic 
complication after surgery or trauma (3). 
There are four types of XIII factor 
common polymorphism that are due to the 
amino acidic changes in Val34Leu, 
Pro564Leu, Val650Ile and are Glu651Gln 
(3). Tyr204Phe polymorphism recently has 
been known (4). Among these 
polymorphisms, G to T common 
polymorphism leads to Val substitution by 
Leu at a distance of 4 amino acid of being 
activated site of thrombin (Arg37-Gly38) 
in A subunit with position 35 (5, 6). 
This polymorphism leads to the excessive 
interaction with thrombin surface of 
proximate of the amino acidic changes to 
being activated site of thrombin and causes 
to increase in vitro cross bindings and this 
causes the excessive activation of factor in 
the body. 
In vivo antithrombotic effects may be 
observed because of being consumed the 
mutant protein of circulation (5). Val34 
wild-type thrombin activates XIII factor, 
two and a half times slower than Val34Leu 
polymorphism . 
Fibrin faster cross bindings and the 
structural differences have caused to 
increase polymorphism activity. Trans 
glutaminase proprietary activity of FXIIIA 
factor and its plasmatic rate as a result of 
this polymorphism do not change (2, 7), 
only accelerates being activated plasmatic 
XIII factor Leu allele due to the release of 
activation peptide through thrombin from 
plasmatic protein of mutant dramatically 
and therefore, occurs more quickly (2, 8). 
Due to high rate of being activated, XIII 
factor can cause the ineffective cross-
linking and or because of FXIIIA effects 
on other proteins disturbs their kinetics of 
the binding reactions (6). 
Being homozygote causes more activity 
whereas the heterozygote carriers show an 
intermediate enzymatic activity (9) so that 
in Leu34 variant, Lag phase between the 
formation of fibrin and FXIIIA separation 
is obviously shorter than Val34 variant 
(10). So far, the several types of different 
polymorphism have been reported about 
XIII factor. 
FXIIIVal34Leu polymorphism has the 
most important role in the activity of XIII 
factor. Many investigations have been 
conducted in relationship with this 
polymorphism and the cardiac, venous, 
and cerebral thrombic events that their 
results are contradictory. The results of 
some researches show that this 
polymorphism is considered as a 
protective factor for the risk of coronary 
heart, myocardial infarction, early inside 
hemorrhage, venous and cerebral 
thromboembolism diseases (7, 11, 12) 
The protective effects of this 
polymorphism on the mentioned factors 
have not been established in other number 
of investigations (13,14). The protective 
effects of this polymorphism on 
thrombosis have been reported in some 
studies only in one gender. The proposed 
mechanisms in often investigations show 
that FXIIIVal34Leu point mutation 
probably causes to form weaker fibrin 
structures and thus, leads resistance 
against the cerebral and cardiac infarction 
and reduces the susceptibility to 
thrombosis (8). 
Considering that major thalassemic 
patients are susceptible to increase of the 
chronic coagulability with the increased 
incidence of thromboembolic events (18-
15) and furthermore, so far, a study hasn’t 
been conducted to investigate the 
prevalence of FXIIIVal34Leu 
polymorphism in major thalassemic 
patients in Iran and the world thus, this 




study has been conducted with aim to 
determine the prevalence of 
FXIIIVal34Leu polymorphism and its 
relationship to the gender in patients with 
major thalassemia referring to Thalassemia 
Center of Ilam City. 
Materials and methods 
The study has been from the case-control 
type and the studied population was the 
thalassemic patients referring to 
Thalassemia Center of Ilam City. The 
sampling was conducted as census with 
the referral order on the different days so 
that based on calculation for each case 
group, the number of 100 patients with 
thalassemia, including 50 males and 50 
females were investigated . 
The number of 100 healthy subjects 
compatible in terms of age and gender was 
selected as control. After preparing 10 ml 
of venous blood sample from participants, 
DNA extraction was conducted from the 
bloody samples. 
Designing primers was conducted in 
making-kit ward of Iran (Tehran) Blood 
Transfusion Organization. DNA after 
extraction by using Roche kit was 
investigated by the proliferation method 
and creating the restrictive area. Sequence 
of the primers was as follows. 
R: GTTGACGCCCCGGGGCACCG 
F: ACTTCCAGGACCGCCTTTGGAGGC 
Following proliferative instruction was 
used to duplicate FXIIIVal34Leu for PCR 
reaction of thermo cycler program. 
Initial denaturation for 5 min at 95 °C, 40 
cycles of denaturation (Denaturation for 1 
min at 95 ° C, Annealing for 1 min at 55 
°C, Extension for 1 min at 72 °C) and a 
final extension phase for 5 min at 72 ° C 
were conducted. It should be mentioned 
because of ensuring FXIIIVal34Leu 
correct and appropriate proliferation for 
any sample, electrophoresis was conducted 
in agarose gel 1.5 % (with voltage of 120 
V for 20 min), and if the absence of seeing 
a band bp 114 for the related sample, PCR 
again was conducted. RFLP was 
conducted for FXIIIVal34Leu. DNA 
pieces (bands) that had become to the 
orange color in the presence of existed 
ethidium bromide in the gel against UV 
ray were seen. Existence of band bp 114 
indicated the accuracy of extraction and 
DNA adequacy as well as absence of Taq 
polymerase inhibitor. The electrophoresis 
of PCRFXIIIVal34Leu products was 
conducted after RFLP. 
While the length of PCR product was 114 
bp that after the enzymatic digestion due to 
lacking the site of break for Cfo1 enzyme 
in homozygotic individuals, only one band 
(114 bp), in heterozygotic individuals, 
both the bands, intact and digested (94 and 
114 bp) and in Wild Type individuals, 
only a 94 bp are observed that indicates 
the complete digestion. The used 




The characterized G nucleotide shows an 
incongruity in 3' end of the reverse primer 
(original nucleotide A) that is for 
establishing a site of break for Cfo1 
enzyme in the normal sequence (GCGC) 
that is lost in the presence of Leucine 
allele (GCTC). 
Analysis of the data was conducted by 
SPSS 16 software, chi-square, and logistic 
regression statistical tests. P<0.05 was 
considered as the significant level. 
Results  
The results showed that 18% (18 persons) 
had Val34Leu polymorphism that 83% and 
17% (15 and 3 persons) of them, 
respectively, were the heterozygotic and 
homozygotic. 26% (26 persons) had 
Val34Leu polymorphism in the control 
group that 73% and 27% (19 and 7 
persons) of them were, respectively, 
heterozygotic and homozygotic. Based on 
the findings, a significant relationship 
weren’t observed between the prevalence 




of FXIIIA Val34Leu polymorphism in the 
thalassemic patients (p= 0.07) and also 











                              Figure 1. The obtained result after the digestion by Cfo1enzyme. 1, Homozygote; 
                              2, Heterozygote; 3, Wild type; 4, Size marker (50 bp). 
 
Discussion 
No significant statistical differences 
existed in present study between the 
prevalence of FXIIIA Val34Leu 
polymorphism (p= 0.07) and gender (p= 
0.08) in both case and control groups. 
According the conducted search, so far, 
the prevalence of FXIIIA Val34Leu 
polymorphism has not been reported in 
major thalassemic patients but its rate of 
prevalence has been investigated in other 
countries in healthy individuals and some 
certain diseases and in the different 
races.Its prevalence has been reported in 
Korea country like Japan at zero limit and 
in another investigation, 2.5% (19). The 
prevalence of Leu34 mutant allele among 
the healthy individuals varies from 3%-
44%. 
Furthermore, a significant relationship 
exists between the prevalence of allele and 
the different races. Negros and Caucasians 
similarly shows a high prevalence of allele 
so that its prevalence is, respectively, 
44.3% and 28.9% in Caucasians and 
Negros, while this amount is obviously 
lower in Asians. Japanese individuals have 
a lower rate than Turkish people. Its 
prevalence also has been reported in 
Caucasians, 25-30%. The prevalence of 
Val34Leu polymorphism with Val34 and 
Leu34 allele frequencies was obtained, 
respectively, 73% and 27% in an 
investigation on Caucasian-descent 
Australian 150 (1, 2, 20). 
A significant difference wasn’t observed in 
the present study between the prevalence 
of this polymorphism and gender in the 
thalassemic and control individuals but, 
the protective effect of this polymorphism 
was observed in an investigation only in 
males (21). 
Obviously, differing group of the present 
studied group justifies presence of the 
difference in the results. Investigating this 
polymorphism can be a basis for the future 
researches in field of its prevalence in the 
different races and related diseases. 
Although thrombosis is common in the 




thalassemic patients and these individuals 
are prone to thrombosis, but in this study, 
the diagnostic facilities of individuals 
number with thrombosis didn’t existed in 
the thalassemic patients. Thus, conducting 
such a study is suggested. 
Furthermore, due to the high prevalence of 
this polymorphism in this study than Asian 
countries, conducting study with a greater 
volume of sample and investigation on 
specific thrombotic groups with the 
acquired risk factors such as taking oral 
contraceptive pellets (OCP), surgery 
history, and the long-term immobility can 
help more recognition of its effects on 
patients. 
Conclusion 
A significant relationship wasn’t seen in 
this study between the prevalence of 
FXIIIA Val34Leu polymorphism in the 
thalassemic patients than the control 
group. Conducting studies with larger 
sample size with the associated genetic 
risk factors is recommended. 
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